BACKGROUND: Cell--cell adhesion molecules such as desmosomes and cytokeratins may play a major role in epithelial--mesenchymal transition and have been suggested to have a relevant impact on tumour progression. This study investigated 15 biomarkers in pancreatic ductal adenocarcinoma (PDAC) and correlated the results with clinicopathological parameters. METHODS: Tissue microarrays of 115 R0-resected PDAC were constructed to evaluate the protein expression of 15 in genome-wide expression profiling differentially expressed biomarkers. RESULTS: At the protein level a high expression of desmocollin 2 (DSC2) was observed in 90.4%, DSC1 (67.6%), DSC3 (0.9%), MDM2 (16.2%), CEA (64.8%), CK7 (85.2%), CK8 (96.5%), CK18 (96.5%), CK19 (93.9%), CK20 (11.5%), CA19-9 (86.6%), TLE1 (8.7%), PITX1 (91.2%), factor H (95.7%) and mesothelin (9.6%). Reduced expression of DSC2 was statistically correlated with shorter patient survival, higher tumour grading and positive lymph node status (p=0.008, p=0.029, p=0.011, respectively). In multivariable analysis reduced expression of DSC2, higher tumour grading and positive lymph node status were independently correlated with shorter patient survival. CONCLUSIONS: Reduced expression of DSC2 is independently correlated with shorter patient survival, higher tumour grading and positive lymph node status in PDAC and could serve as a prognostic marker.
BACKGROUND: Cell--cell adhesion molecules such as desmosomes and cytokeratins may play a major role in epithelial--mesenchymal transition and have been suggested to have a relevant impact on tumour progression. This study investigated 15 biomarkers in pancreatic ductal adenocarcinoma (PDAC) and correlated the results with clinicopathological parameters. METHODS: Tissue microarrays of 115 R0-resected PDAC were constructed to evaluate the protein expression of 15 in genome-wide expression profiling differentially expressed biomarkers. RESULTS: At the protein level a high expression of desmocollin 2 (DSC2) was observed in 90.4%, DSC1 (67.6%), DSC3 (0.9%), MDM2 (16.2%), CEA (64.8%), CK7 (85.2%), CK8 (96.5%), CK18 (96.5%), CK19 (93.9%), CK20 (11.5%), CA19-9 (86.6%), TLE1 (8.7%), PITX1 (91.2%), factor H (95.7%) and mesothelin (9.6%). Reduced expression of DSC2 was statistically correlated with shorter patient survival, higher tumour grading and positive lymph node status (p=0.008, p=0.029, p=0.011, respectively). In multivariable analysis reduced expression of DSC2, higher tumour grading and positive lymph node status were independently correlated with shorter patient survival. CONCLUSIONS: Reduced expression of DSC2 is independently correlated with shorter patient survival, higher tumour grading and positive lymph node status in PDAC and could serve as a prognostic marker.
Authors: Dominik Riss; Johannes Pammer; Matthaeus C Grasl; Alexandra Kaider; Sven Schneider; Boban M Erovic Journal: Wien Klin Wochenschr Date: 2014-10-10 Impact factor: 1.704
Authors: V Thumbigere-Math; B S Michalowicz; E P de Jong; T J Griffin; D L Basi; P J Hughes; M L Tsai; K K Swenson; L Rockwell; R Gopalakrishnan Journal: Oral Dis Date: 2013-11-29 Impact factor: 3.511
Authors: Katinka Rüping; Annelore Altendorf-Hofmann; Yuan Chen; Eric Kampmann; Sebastian Gibis; Lars Lindner; Detlef Katenkamp; Iver Petersen; Thomas Knösel Journal: J Cancer Res Clin Oncol Date: 2014-05-08 Impact factor: 4.553